Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 8/20 | 0.37 |
| ▸ | FAAH | O00519 | 7/20 | 0.37 |
| ▸ | ACHE | P22303 | 7/20 | 0.37 |
| ▸ | BCHE | P06276 | 5/20 | 0.37 |
| ▸ | ACLY | P53396 | 1/20 | 0.34 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.34 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.34 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.34 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL493746 | 0.98 | PTGIR (0.37) | PTGIRFAAHACHEBCHECACNA2D1 | |
| SCHEMBL492921 | 0.95 | THRB (0.35) | PTGIRFAAHACHEBCHE | |
| SCHEMBL493458 | 0.93 | THRB (0.36) | PTGIRFAAHACHEBCHECACNA2D1 | |
| SCHEMBL493532 | 0.89 | SMN1; SMN2 (0.39) | ACLYCACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL493404 | 0.88 | SMN1; SMN2 (0.38) | ACLYCACNA2D1CACNA1BCACNB1CACNA1C | |
| SCHEMBL493595 | 0.87 | FAAH (0.38) | FAAHACHEBCHE | |
| SCHEMBL493572 | 0.86 | PTGIR (0.39) | PTGIRFAAHACHE | |
| SCHEMBL493261 | 0.86 | PTGIR (0.38) | PTGIRFAAHACHEBCHEACLY | |
| SCHEMBL493623 | 0.86 | PTGIR (0.40) | PTGIRFAAHACHEBCHE | |
| SCHEMBL493272 | 0.85 | FAAH (0.38) | PTGIRFAAHACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | claimed |
| EP-2139851-A2 | SUBSTITUTED AMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2010-01-06 | — | — | EP | claimed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | claimed |
| WO-2008131946-A2 | SUBSTITUTED AMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2008-11-06 | — | — | WO | claimed |
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306084-A1 | Substituted Amide Compounds | OPRK1, NAA50, ACMSD | PTGIR 121/4885FAAH 6/4885ACHE 52/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.